



1fw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket Number: SSBC-0001 (121300.00003)
In re the Application of: Fang Hu
Serial No.: 10/766,307
Filed: January 28, 2004
Art Unit: 1642
Examiner: Unknown
For: THERAPY FOR PRIMARY AND METASTATIC CANCER

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

CERTIFICATE OF MAILING: I hereby certify that this correspondence is addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, and is being deposited with the United States Postal Service on 7-24-06

Tracy E. Giroux
(Printed or typed name of person signing certificate)
Tracy E. Giroux
(Signature of the person signing the certificate)

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Herewith is Form PTO-1449 together with one copy of each document listed thereon. Please note also any item(s) designated below:

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, which ever event occurs last 37 C.F.R. § 1.97(b).

The fee set forth in 37 CFR 1.17(p) _____ is enclosed _____ may be charged to Deposit Account Number 50-1752.

Each document listed on enclosed Form PTO-1449 was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this correspondence.

X

Respectfully submitted,

T. Ling Chwang
T. Ling Chwang
Reg. No. 33,590

Date: July 24, 2006

Jackson Walker L.L.P.
901 Main Street, Suite 6000
Dallas, Texas 75202
Phone: (214) 953-5959
Fax: (214) 661-6870



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

<i>Complete if Known</i>	
Application Number	10/766,307
Filing Date	January 28, 2004
First Named Inventor	Fang Hu
Art Unit	1642
Examiner Name	Unknown
Attorney Docket Number	SSBC-0001 (121300.00003)

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	1	WO 01/08709 A1	02/08/2001	Anwer, et al.	Entire Document

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/766,307
				Filing Date	January 28, 2004
				First Named Inventor	Hu Fang
				Art Unit	1642
				Examiner Name	Unknown
Sheet	2	of	3	Attorney Docket Number	SSBC-0001 (121300.00003)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2	BISCHOFF JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996 Oct 18;274(5286):373-6.	
	3	BORRELLI MJ, Schoenherr DM, Wong A, Bernock LJ, Corry PM. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells. Cancer Res. 2001 Feb 1;61(3):1113-21.	
	4	GERICKE D, Dietzel F, Konig W, Ruster I, Schumacher L. Further progress with oncolysis due to apathogenic clostridia. Zentralbl Bakteriol [Orig A]. 1979 Mar;243(1):102-12.	
	5	GERICKE D, Dietzel F., Konig, W. Mikrowellenhyperthermie und Onkolyse Durch Clostridien. Naturwissenschaften, Springer Verlag, Berlin, DE. 1975;62(11):541-542.	
	6	GIANNIOS, J. Wt-p53 Gene Treatment Combined with Hyperthermia and Vinorelbine Induce Apoptosis After Ionising-Radiation on Radioresistant Human Colon Adenocarcinoma Cells. Romania Journal of Gastroenterology. 1998;7(2):95-103.	
	7	ITO A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther. 2001 Sep;8(9):649-54.	
	8	LI CY, Dewhirst MW. Hyperthermia-regulated immunogene therapy. Int J Hyperthermia. 2002 Nov-Dec;18(6):586-96.	
	9	OKAMOTO K, Shinoura N, Egawa N, Asai A, Kirino T, Shibusaki F, Shitara N. Adenovirus-mediated transfer of p53 augments hyperthermia-induced apoptosis in U251 glioma cells. Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):525-31.	
	10	QI V, Weinrib L, Ma N, Li JH, Klamut H, Liu FF. Adenoviral p53 gene therapy promotes heat-induced apoptosis in a nasopharyngeal carcinoma cell line. Int J Hyperthermia. 2001 Jan-Feb;17(1):38-47.	
	11	THYRELL L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002 Feb 14;21(8):1251-62.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*Complete if Known***INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

Application Number

10/766,307

Filing Date

January 28, 2004

First Named Inventor

Hu Fang

Art Unit

1642

Examiner Name

Unknown

Attorney Docket Number

SSBC-0001 (121300.00003)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	TOMASOVIC SP, Khodadadian M, Hung MC, Klostergaard J. Hyperthermia enhances the cytotoxicity of National Institutes of Health 3T3 cells transfected with a noncleavable transmembrane pro-tumor necrosis factor deletion mutant. <i>J Immunother Emphasis Tumor Immunol.</i> 1994 Oct;16(3):181-7.	
	13	WALTHER W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes. <i>Int J Cancer.</i> 2002 Mar 10;98(2):291-6.	
	14	WANG JH, Yao MZ, Gu JF, Sun LY, Shen YF, Liu XY. Blocking HSF1 by dominant-negative mutant to sensitize tumor cells to hyperthermia. <i>Biochem Biophys Res Commun.</i> 2002 Feb 8;290(5):1454-61.	
	15	WATANABE N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. <i>Cancer Res.</i> 1988 Feb 1;48(3):650-3.	
	16	ZEH HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. <i>Cancer Gene Ther.</i> 2002 Dec;9(12):1001-12.	
	17	European Search Report Under Rule 112 EPC, from the European Patent Office, dated May 2, 2006.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.